ArticleFrontiers in genetics2025
Single-cell RNA-seq combined with bulk RNA-seq explores shared gene signatures between thyroid and breast cancers.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to identify key genes that are common to both breast cancer and thyroid cancer, as well as to determine shared therapeutic targets relevant to both conditions. Methods: We utilized transcriptome data from both breast and thyroid cancers, along with single-cell data, and applied cell deconvolution techniques to evaluate the extent of monocyte infiltration. Tumor-related gene modules were identified through weighted gene co-expression network analysis (WGCNA), followed by enrichment analysis to uncover significant signals shared within these gene modules. A machine learning approach was then employed to pinpoint hub genes. Additionally, RT-qPCR was performed to validate the expression levels of these hub genes in tumor and adjacent non-tumor tissues from patients with both cancer types. Results: Our analyses revealed that the transcriptional networks of breast cancer and thyroid cancer display significant similarities. WGCNA identified two consensus modules that are strongly associated with both cancers and monocyte infiltration. Enrichment analysis highlighted glycosaminoglycan synthesis pathways as critical signals that are common to both cancers. A total of seven hub genes were identified using the machine-learning approach. Results from RT-qPCR and immunohistochemistry in clinical samples showed that the expression levels of PILRA, Mki67, and UBE2C were markedly different between cancerous and adjacent tissues. Conclusion: PILRA, MKI67, and UBE2C, as potential diagnostic and prognostic biomarkers, are anticipated to serve as promising therapeutic targets for the clinical management of both breast cancer and thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.